Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Akabani

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
International Journal of Radiation Biology|August 18, 2000
Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetryE Aurlien, R H Larsen, G Akabani, et al.
IEEE Transactions on Medical Imaging|July 14, 2005
Molecular imaging of small animals with a triple-head SPECT system using pinhole collimationS D Metzler, R J Jaszczak, N H Patil, et al.
International Journal of Radiation Oncology, Biology, Physics|September 16, 1999
Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysisR E McLendon, G E Archer, R H Larsen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 26, 1998
Locally increased uptake of fluorine-18-fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumorsC J Marriott, W Thorstad, G Akabani, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 21, 1999
Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumorsG Akabani, C J Reist, I Cokgor, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 1997
Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49P K Leichner, G Akabani, D Colcher, et al.
Cancer|May 4, 2001
Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case studyI Cokgor, G Akabani, H S Friedman, et al.
International Journal of Radiation Oncology, Biology, Physics|March 8, 2000
Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapyG Akabani, I Cokgor, R E Coleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2000
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomasI Cokgor, G Akabani, C T Kuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial resultsD D Bigner, M T Brown, A H Friedman, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
International Journal of Radiation Biology|August 18, 2000
Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetryE Aurlien, R H Larsen, G Akabani, et al.
IEEE Transactions on Medical Imaging|July 14, 2005
Molecular imaging of small animals with a triple-head SPECT system using pinhole collimationS D Metzler, R J Jaszczak, N H Patil, et al.
International Journal of Radiation Oncology, Biology, Physics|September 16, 1999
Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysisR E McLendon, G E Archer, R H Larsen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 26, 1998
Locally increased uptake of fluorine-18-fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumorsC J Marriott, W Thorstad, G Akabani, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 21, 1999
Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumorsG Akabani, C J Reist, I Cokgor, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 1997
Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49P K Leichner, G Akabani, D Colcher, et al.
Cancer|May 4, 2001
Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case studyI Cokgor, G Akabani, H S Friedman, et al.
International Journal of Radiation Oncology, Biology, Physics|March 8, 2000
Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapyG Akabani, I Cokgor, R E Coleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2000
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomasI Cokgor, G Akabani, C T Kuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial resultsD D Bigner, M T Brown, A H Friedman, et al.
Pageof 2